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Women urgently need a self-initiated, multipurpose prevention technology (MPT) that simultaneously reduces
their risk of acquiring HIV-1, HSV-2, and HPV (latter two associatedwith increased risk of HIV-1 acquisition) and
prevents unintended pregnancy. Here, we describe a novel core–matrix intravaginal ring (IVR), the MZCL IVR,
which effectively delivered the MZC combination microbicide and a contraceptive. TheMZCL IVR contains four
active pharmaceutical ingredients (APIs):MIV-150 (targets HIV-1), zinc acetate (ZA; targets HIV-1 and HSV-
2), carrageenan (CG; targetsHPV andHSV-2), and levonorgestrel (LNG; targets unintended pregnancy). The elas-
tomeric IVR body (matrix) was produced by hot melt extrusion of the non-water swellable elastomer, ethylene
vinyl acetate (EVA-28), containing the hydrophobic small molecules, MIV-150 and LNG. The solid hydrophilic
core, embeddedwithin the IVR by compression, contained the smallmolecule ZA and themacromolecule CG.Hy-
drated ZA/CG from the corewas released by diffusion via a pore on the IVRwhile theMIV-150/LNG diffused from
the matrix continuously for 94 days (d) in vitro and up to 28d (study period) in macaques. The APIs released
in vitro and in vivo were active against HIV-1ADA-M, HSV-2, and HPV16 PsV in cell-based assays. Serum LNG
was at levels associated with local contraceptive effects. The results demonstrate proof-of-concept of a novel
core–matrix IVR for sustained and simultaneous delivery of diverse molecules for the prevention of HIV, HSV-2
and HPV acquisition, as well as unintended pregnancy.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Topical microbicides are usually self-administered pharmaceutical
preparations for both women and men, containing antiretroviral
(ARV) and or non-ARV active pharmaceutical ingredients (APIs)
targeted to prevent sexually transmitted infections (STIs) [1]. The APIs
are generally formulated as gels, foams, intravaginal rings (IVRs),
electrospun nanoﬁbers, pessaries, douches, diaphragms, suppositories
and tablets. The status of microbicide formulation development has
been reported prior in comprehensive reviews [2,3]. Focusing on vul-
nerable populations, microbicide developers seek to improve women's
sexual and reproductive health (SRH), by targeting primarily HIV-1 pre-
vention [4,5] and, in some instances, unwanted pregnancy [6–8]. This
approach does not protect women from other prevalent non-curable
viral STIs such as herpes simplex virus-2 (HSV-2) and human papilloma
virus (HPV).While some APIs have anti-HIV/HSV-2 [9,10] activity, there
is no broad spectrum multipurpose prevention technology (MPT) that
can simultaneously prevent these threemajor viral STIs and unintended
pregnancy. HPV or HSV-2 can pose collateral risks to women's SRH.
There is an increased susceptibility to HIV-1 acquisition [11–14], HPV
causes cervical cancer [15], and neonatal HSV-2 infections render high
mortality rate in both, mothers and infants. Daily there are nearly
5700 new HIV-1 infections [16], 4000 AIDS-related deaths [16], 35,000
new HSV-2 infections in women [17], 700 HPV-related deaths [18],
200,000 unplanned pregnancies [19], 125,000 abortions [19] and 800
pregnancy-related deaths worldwide [20]. Further, high-risk, low
income populations of Sub-Saharan Africa and South/West Asia are
vulnerable to SRH challenges and would beneﬁt greatly from women-
initiated products that simultaneously prevent STIs and unintended
pregnancy [21].
While vaccine(s) will likely have substantial beneﬁts, HIV-1 and
HSV-2 vaccines [22] are still being developed or tested and the
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marketed HPV vaccines [23–25] are effective against (up to) nine HPV
subtypes but not 31 other HPVs associated with anogenital infections
[24,26,27]. Besides, vaccines may require cold storage which will limit
accessibility in resource-poor regions and have low uptake mainly due
to parental concerns and high cost. Thus, there is an urgent need to
develop women initiated, low cost MPTs that are amenable to diverse
populations [21].
The results of the Phase 2b CAPRISA-004 trial (39% reduction in HIV-
1 and 50% reduction in HSV-2) of a coitally dependent 1% tenofovir
(TFV) gel [28] has encouraged the ﬁeld to develop topical intravaginal
formulations. But the MTN-003 VOICE trial which assessed efﬁcacy
and safety of short term oral and vaginal formulations — tenofovir
disoproxil fumarate (TDF) and tenofovir-emtricitabine (TDF-FTC) oral
tablets, and 1% TFV vaginal gel to be used daily for 12–33 months [29],
indicated that therewas nodifference in the efﬁcacy between the tested
microbicides and the placebo group. However, a subset analysis of 1%
TFV gel treated group conﬁrmed that women with TFV detected in
their plasma were at a signiﬁcantly lower risk of acquiring HIV-1. On
the heels of the VOICE trial, recently published results from the FACTS
001 study, [30] which was conducted to conﬁrm the results of
CAPRISA-004 trial but with a larger sample size (in order to warrant li-
censure to 1% TFV gel), also indicated that there was no signiﬁcant pro-
tection between the groups using 1% TFV gel and placebo gel. However,
moderate protection was observed in the group who used the product
consistently [30]. Overall, the data from the clinical trials strongly
suggest that the protection correlates with user adherence. For better
adherence and longer term protection, locally acting, non-coitally de-
pendent products such as sustained release intravaginal rings (IVRs)
would be a better choice. An IVR user adherence study in Sub-Saharan
Africa has been reported earlier [31]. For the current development
status of MPT IVRs, readers can refer to [8].
We designed an MPT IVR to release an effective broad spectrum
combination microbicide and a contraceptive for 90 days (d): MIV-
150, ZA, CG, and LNG. MIV-150, a non-nucleoside reverse transcriptase
inhibitor (NNRTI), signiﬁcantly protectedmacaques from SHIV-RT chal-
lenge [32-37] and limited the emergence of NNRTI resistant mutations
in SHIV-RT infected macaques carrying a high dose MIV-150 IVR [38].
Zinc salts have shown broad spectrum antiviral activity including HIV-
1 [39] and HSV [40]. CG, a high molecular weight (MW) linear sulfated
polysaccharide extracted from red seaweed showed potent in vitro and
in vivo antiviral activity against HPV [24,26,41-43] with proven safety
for topical use [44,45]. Additionally, highly compliant Carraguard
(3 wt.% carrageenan gel) users in the Phase 3 trial were associated
with lower risk of HPV infection (vs. methyl cellulose placebo gel
users) [46]. ZA (low MW metal salt)/CG, showed antiviral synergy
against HSV-2 in vitro [47], signiﬁcant protection in a high dose vaginal
and rectal challenge in vivo in mice [47,48] and reduced SHIV-RT infec-
tion in macaques [48]. LNG, a second generation progestin, is an FDA
approved contraceptive with anti-ovulatory properties. It is available
in different formulations and included in the WHO's model list of
essential medicines [49].
The MZC combination microbicide gel protected mice against SHIV-
RT, HSV-2, and HPV infections— both vaginally and rectally [50], signif-
icantly protectedmacaques against SHIV-RT and partially against HSV-2
in a high dose as well as low dose repeat SHIV-RT/HSV-2 co-challenge
[33,51], and signiﬁcantly reduced HSV-2 shedding in the latter [51,52].
These promising results led to the development of anMZCL IVR. But,
designing a long acting (90d) MPT IVR, to simultaneously release MZCL
can be challenging for three main reasons: i) developing one-body IVR
architecture to release two hydrophilic, one small and one large mole-
cule (ZA and CG), and two hydrophobic small molecules (MIV-150
and LNG). The differences in size and solubilities of APIs in one polymer
limits one-matrix system approach to deliver APIs (Table 1). ii) provid-
ing an extended release of the APIs for as long as 90d (vs. 1 d to 1 week
for short term formulations) and iii) keeping end user experience in
mind, preserving the simple IVR form such that multiple APIs can be
accommodated without manipulating the design (additional external
attachments to hold more APIs).
To address these challenges we developed a core–matrix IVR in
which the hydrophilic and hydrophobic APIs were housed separately.
A core containing hydrophilic APIs was sandwiched between ethylene
vinyl acetate copolymer, grade 2803G (EVA-28), matrices containing
hydrophobic APIs. A pore was drilled on the surface of the IVR to create
a pathway for the release of hydrated core components. Thus, hydro-
philic APIs were released from EVA matrix (usually regarded as an un-
suitable carrier for the hydrophilic API) in a simple IVR form. The
in vitro target release proﬁle was ≥4 μg/d MIV-150, ≥50 μg/d zinc ace-
tate, ≥100 μg/d CG, and ≥2 μg/d LNG. Also, we investigated how
in vivo factors like cervical mucus secretion, blood, shedding of epithe-
lial cells, and limited vaginal ﬂuid volume might affect elution of core
APIs via pore(s). Here, we demonstrate a proof-of-concept of this
novel core–matrix IVR (macaque prototype) by presenting the in vitro
release for 90d, in vivo release in macaques for nearly 28d, and
in vitro efﬁcacy in cell-based assays.
2. Materials and methods
2.1. Core–matrix IVR fabrication
CG (95:5, lambda: kappa) was supplied by Industrial Research Lim-
ited (Wellington, New Zealand). Crystalline ZA, USP grade, Spectrum
Chemicals (New Brunswick, NJ), was jet milled to less than 5 μm at Par-
ticle Sciences Inc. (Bethlehem, PA) using a Sturtevant sanitary design
micronizer. MIV-150 was manufactured by Uquifa (Barcelona, Spain)
and micronized to about 5 μm by Particle Sciences Inc. LNG was pur-
chased from Crystal Pharma (Valladolid, Spain). EVA (grade 2803G)
was supplied by Celanese (Florence, KY) and cryoground by ICO poly-
mer Inc. (Akron, OH). The pellets for IVR matrix were processed at
Particle Sciences Inc. Cryoground EVA-28 was mixed with MIV-150
(0.5 wt.%) alone or with LNG (0.1 wt.%) in a GlenMills T2F Turbula
mixer (Clifton, NJ) and extruded using a Leistritz hot melt extruder
(Nürnberg, Germany). The extruded strands were pelletized with a
Scheer Bay BT-25 pelletizer (Bay City, MI). Placebo pellets (no APIs)
were produced similarly. Carbide drill bits, ~500 μm and ~800 μm
(yielded pore size of 720 μm), used to fabricate pores on the IVRs
were purchased from Drill Bit City (Chicago, IL). All solvents were
HPLC grade.
Using customized molds, Garner Industries (Lincoln, Nebraska),
EVA-28 pellets pre-compounded with MIV-150 (±LNG) were melt
extruded (120 psi, 245 °F) to produce half IVRs with a central cavity
(concentric to the outer diameter) for the core (Suppl. Fig 1, method
1). ZA/CG (3/7) mixture was compressed within the core cavity to ﬁll
it. The same matrix was extruded on top to form a full IVR, MZC or
MZCL IVR. Thus, one half of the IVR was a matrix containing the core
(core side) while other half was pure matrix. The target loadings per
IVR were 3 mg MIV-150, 30 mg ZA, 70 mg CG and 0.6 mg LNG. The
IVRs were subjected to an overnight leak test (Suppl. method 2). Core
side pores (pores bored from the IVR surface into the core, 1 pore per
IVR) of 500 μm and 800 μm and through pore (pore formed through
the cross section of the IVR, 2 pores per IVR) of 500 μm were tested.
The 800 μmpores (but not 500 μmdue to small pore size) were plugged
with the core material to provide instantaneous release and potentially
limit pore clogging in vivo. Microscopy was performed on the pores
(Suppl. method 3). Taken together, we tested 500 μm pored (core side
and through) MZC/ MZCL, 800 μm (core side) MZC, and placebo (EVA-
28 matrix) IVRs. Details of the different IVR conﬁgurations tested are
listed in Table 2.
2.2. Quantiﬁcation of APIs
A literature method for ZA [53] was optimized (Suppl. method 4),
LLOQ: 0.1 μg/ 200 μL (volume plated in the well). CG was analyzed by
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colorimetic UV assay using methylene blue [54], LLOQ: 0.12 μg/ 200 μL.
MIV-150, LLOQ: 0.096 μg/mL at 10 μL injection volume, and LNG,
LLOQ: 0.32 μg/mL at 10 μL injection volume, were analyzed using the
HPLC method described for MIV-150 in [36] except that the gradient
progressed from90% (mobile phaseA-200mMammoniumacetate buff-
er) to 10% (mobile phase B-acetonitrile) in 15 min. HPLC by Agilent
systems (Santa Clara, CA), series 1100 was used. LNG was detected at
245 nm wavelength.
2.3. Determination of API content in the matrix
MIV-150 and LNG were extracted by dissolving ~50 mg of IVR
matrix in 2 mL of chloroform with overnight shaking and then adding
methanol [55]. The solution was ﬁltered using a 0.2 μm PTFE ﬁlter, Pall
(Port Washington, NY) and theMIV-150 and LNG content of the ﬁltrate
was analyzed using HPLC as per method in (2.2) by making 10 μL injec-
tions. Spike control recovery (known amount of analyte added to a
blank EVA-28 matrix) for MIV-150 and LNG were 99 ± 4% and 95 ±
5%, respectively.
2.4. In vitro release
The release testing was performed on a whole MZC/ MZCL IVR in
10 mL (sink condition for hydrophilic APIs and non-sink condition for
hydrophobic APIs) of 25 mM acetate buffer, pH 4.2, at 37 °C with shak-
ing at 100 rpm for 94dwith daily media replacement and periodic sam-
pling. The release eluent was assayed for all APIs as described above.
The release of ZA and CG was modeled to a power function
Y ¼ αtβ ð1Þ
where, Y= the average cumulative release,α=release coefﬁcient, t =
time, β = exponent that deﬁnes the type of release where β = 1
denotes linear release and β ≠ 1 non-linear release.
To utilize MIXED procedure model (Suppl., method 5) the power
function was log-transformed so that a linear mixed-effect model that
provides estimates of α and β on the log-scale while accounting for
repeated measurements can be performed. This allows assessing differ-
ences in pore size and the effect of LNG (MZC vs. MZCL IVRs) on the
release of core components.
2.5. Pharmacokinetic (PK) studies in macaque model
Ethics statement: Adult female rhesus macaques (Macaca mulatta)
of 4–13 years and weighing 5–14 kg were used. The macaques were
housed and treated at the Tulane National Primate Research Center,
TNPRC (Covington, LA) in accordance with the protocol approved by
the Institutional Animal Care and Use Committee (OLAW Assurance
A4499-01), which is accredited by the Association for Assessment and
Accreditation of Laboratory Animal Care (AAALAC000594). All proce-
dures complied with the Animal Welfare Act [56], the Guide for the
Care and Use of Laboratory Animals [57], and TNPRC standards for min-
imizing animal distress. Macaques were conﬁrmed negative for SIV,
simian type D retroviruses, simian T cell leukemia virus-1 and herpes
B and were randomized to treatment groups.
The following IVR groups (Table 2) were tested in non-Depo-
Provera (non-DP) treated macaques for 23 or 28d.: 500 μm core
side — MZC (n = 10) and MZCL (n = 3), 500 μm through — MZC
(n = 11) and MZCL (n = 3), 800 μm core side with a plug — MZC
(n = 4) and placebo IVRs (n=2). The IVRs were inserted with the
core side facing the cervix. Vaginal pH at the baseline and during the
study was measured by pH paper, EMD Millipore Corp (Billerica, MA)
which was inserted into the vaginal vault for about 5 min. Vaginal
ﬂuid (VF) was collected using Merocel® spears, Medtronic Xomed
(Jacksonville, Florida) and suspended in 1 mL of saline, EDTA blood
(b10mL/kg/month) was collected at indicated time points as described
[36] and shipped overnight to the Population Council, NY for analysis.
Plasma was isolated from EDTA blood [58]. CG in VF was quantiﬁed
using ELISA (LLOQ: 40 ng/mL) [50] andMIV-150 by radio immunoassay
(RIA), LLOQ: 1 ng/mL or 2.7 nM [34]. MIV-150 in plasma was analyzed
by LCMS/MS (LLOQ: 20 pg/mL or 54 pM) [35]. LNG in serum was mea-
sured by RIA, Immunometrics Ltd (London, UK) at the Oregon National
Primate Research Center (ONPRC), Endocrine Technology and Support
Core Laboratory, ETSC, (Beaverton, OR). The range of detection of the
assay was 23–375 fmol/sample with a sensitivity of 36–47 pg/ml. Post
study, the IVRs were removed from the vaginal tract (without squeez-
ing), rinsed in saline, dried, labeled as per the macaque ID and shipped
overnight at room temperature (RT) to the Population Council, NY for
residual API quantiﬁcation. Post use, the IVRs were sectioned in half to
Table 1
Physicochemical attributes and chemical structures of the APIs.
Compound MW
(g/mol)
Water solubility IVR 
compartment
Micronized MIV–150
(log P: 4.2 ± 0.2 at 25°C)
368.36 0.8 ± 0.05 μg/mL
(at 37°C)
Matrix
Micronized LNG
(log P: 3.4 ± 0.3 at 25°C)
312.45 1.19 ± 0.05 μg/mL
(at 37°C)
Matrix
Zinc acetate dihydrate
(lop P: not reported)
219.51 0.43 g/mL
(at 20°C)
Core
Carrageenan
(log P: not reported)
1,360,000 1g in ≤ 30 mL
(at 80°C)
Core
Structures
MIV–150
LNG
ZA
Lambda CG
Table 2
Different IVR formulations tested in this study.
S. no IVR type Pore size (μm) Pore location No. of pores per IVR
1. MZC 500 Core side 1a
2. MZCL 500 Core side
3. MZC 800 Core side
4. MZC 500 Through 2a
5. MZCL 500 Through
6. Placebo 500 Core side 1
7. Placebo 500 Through 2
a Cross sections shown in Fig. 1b and c.
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elute the residual core components in 10mL, pH 4.2, acetate buffer. APIs
were analyzed as described previously.
2.6. Assessment of progestational activity of LNG in presence of MZC
combination
We separately tested the effect ofMZC combination on the progesta-
tional activity of LNG as described [59], Suppl. method 6. Brieﬂy, CG and
MZC gels without LNG [43] and at two different doses of LNG (50 μg/mL
and 100 μg/mL) were applied intravaginally for 6d. The endometrial
glandular transformation was assessed histologically as per theMcPhail
index [60].
2.7. Activity of eluted MZCL in cell based assays
2.7.1. Cells and viruses
Human PBMCs were isolated from leukopacks, NY Blood Center
(New York, NY) and were activated and grown as previously described
[50]. TZM-bl (NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH),
HeLa and Vero cells (ATCC, Rockville, MD) were cultured as previously
described [47,50]. HIV-1ADA-M and HIV-1BaL were kindly provided by
Dr. Jeffrey Lifson at Leidos Biomedical Research, Inc. Frederick National
Laboratory (Frederick, Maryland) and titered using the TZM-bl assay
[61] or the Reed and Muench formula. HSV-2G strain (ATCC) and
HPV-16 PsV were propagated and titered as previously described [50].
2.7.2. Impact of LNG on antiviral properties of MZC
A concentration range (six-nine dilutions per API) of MIV-150
(11–0.04 nM), ZA (228–0.9 μM, anti-HIV assay) and (300–2.7 μg/mL,
anti-HSV-2 assay), CG (300–2.7 ng/mL, anti-HSV-2 assay) and (2–
0.007 μg/mL, anti-HPV assay) with or without LNG (500 nM) was
prepared in cell culture media. For anti-HIV assay, MIV-150, ZA or
their combination (±LNG) were added to activated PBMCs before
HIV-1BaL challenge as per [43] except that for ZA treatments, same ZA
concentrations were replaced at every media change. Anti-HSV-2 activ-
ity wasmeasured using the HSV-2 plaque assay as previously described
[47]; the anti-HPV assay previously described [26,43] was used to test
CG antiviral activity against HPV16-PsV. All analysis was performed in
triplicate.
2.7.3. Efﬁcacy of in vitro and in vivo released samples in cell based assays
Based on the HPLC assay results for CG andMIV-150, the in vitro re-
lease eluent and VF samples were diluted to generate dose–response
curves from which CC50 and IC50 with 95% conﬁdence intervals (CI)
were computed. We tested the antiviral activity using the TZM-bl
assay for anti-HIV-1ADA-M activity [61] and anti-HPV16 PsV activity
using the luciferase assay (HeLa cells) [26,43]. The dye (PrestoBlue) up-
take assay was used to test the in vitro susceptibility of HSV-2 [62].
Brieﬂy, Vero cells were seeded (104 cells/well) in 100 μL of medium
and incubated overnight at 37 °C, 5% CO2, and 98% humidity. Diluted
release samples were added to cells immediately before adding
85 pfu/well of HSV-2G. Cell controls and cytotoxicity samples received
medium only (no virus). The plates were incubated for 6 d at 37 °C,
5% CO2, and 98% humidity. Cell monolayers were washed with DMEM
without phenol red then 100 μL of 1× Presto Blue reagent was added.
Fluorescence (emission 600 nm and excitation 560 nm) was read on
Gemini EM microplate reader, Molecular Devices (Sunnyvale, CA). All
samples and controls were tested in triplicates.
2.8. Stability of the IVRs
Freshly prepared MZCL IVRs (n= 3)were cut into four sections and
each section was sealed in an aluminum pouch, Sorbent systems (Los
Angeles, CA), using Uline heat sealer (Pleasant Prairie, WI). One section
per IVR was stored at−80 °C (control) and the remaining at 40 °C/75%
RH for three months in a Caron incubator. All APIs were assayed as
described earlier.
2.9. Statistics
Statistical analysis of the in vitro release of APIswas performedusing
a Powermodel in SAS (version 9.4). This model was ﬁt using theMIXED
procedure. One-way Analysis of variance (ANOVA) was performed by
using JMP®, version 11.1.1, SAS Institute Inc. (Cary, NC). In vitro IC50
valueswith the 95% CIwere calculated using a dose–response-inhibition
analysis on GraphPad Prism v5.0c software for Windows (San Diego,
CA). For the correlation between residual APIs (core and matrix),
Spearman analysis in GraphPad Prism was used. For all tests, statistical
signiﬁcance was achieved at p ≤ 0.05.
3. Results
3.1. The novel core–matrix IVR contains hydrophilic and hydrophobic APIs
of different MWs
Fig. 1a (left) shows a prototype macaqueMZCL IVR containing a ZA/
CG core in one half of the IVRmatrix (EVA-28 loadedwithMIV-150 and
LNG); the other half comprised matrix only (no core). Each IVR
contained ZA (34 ± 4 mg, n = 15) and CG (81 ± 10 mg, n = 15). The
IVR matrix contained MIV-150 (3 ± 0.15 mg, n = 15) and in MZCL
IVRs, LNG (0.6 ± 0.04 mg, n = 6). Fig. 1b demonstrates placement of
the core and the matrix APIs within the IVR.
3.2. The core–matrix IVR releases all four API for 94d in vitro
The cumulative and percent cumulative release (CR) of the hydro-
philic ZA and CG (upper row) and hydrophobic MIV-150 and LNG
(lower row) from IVRs with 500 μm pores (core side and through)
and 800 μm pore (core side), plugged, is shown in Fig. 2a. The daily re-
lease of the APIs from the same IVRs is illustrated in Fig. 2b. The release
conditions were sink for ZA and CG, and non-sink for MIV-150 and LNG
throughout the study. The buffer uptake (via the pore) and subsequent
progression of the waterfront was observed in all IVRs (Fig. 2c).
3.2.1. CG release
CG release from 500 μmpored core side IVRs was signiﬁcantly lower
than the release from the 500 μm through pored IVRs (p = 0.0028,
adjusted p-value by Tukey–Kramer test method for multiple
comparisons = 0.0078) and also from 800 μm pored core side IVRs
(p = 0.0056, adjusted p-value by Tukey–Kramer method for multiple
comparisons = 0.0154; Suppl. Table 1), Fig. 2a and b. The differences
in release rates can be distinguished from their daily release proﬁles
(Fig. 2b), where the 500 μm pored (core side) IVRs released CG in a
sustained manner above or at the target release until the end of the
study. At d50, the levels were above target release proﬁle. In contrast,
for the 500 μm pored (through) IVRs and 800 μm pored core side IVRs,
the levels were at the target release at d50 but fell below the target
release rate by d94. There was no signiﬁcant difference between the re-
lease from 500 μmthrough pore and 800 μmpore (p=0.6713, adjusted
p-value by Tukey–Kramer method for multiple comparisons= 0.9053)
or fromMZC andMZCL IVRs with the same pore sizes (p= 0.575), sug-
gesting LNG did not affect CG release from the core. Therefore, CG re-
lease for the same pore conﬁguration (Fig. 2) is represented as pooled
from MZC and MZCL IVRs. Through d31, the average CR (mg/d) was
38 ± 9 (52 ± 17% CR), 56 ± 8 (68 ± 8% CR) and 56 ± 21 (69 ± 31%
CR) from 500 μm (core side), 500 μm (through) and 800 μm core side
pores, respectively. Through d31, the average daily release (mg/d) was
1.3 ± 0.4, 1.1 ± 0.2 and 0.9 ± 0.3 from 500 μm (core side), 500 μm
(through) and 800 μm core side pores, respectively. Post 94d, the % CG
left in 500 μm core, 500 μm through and 800 μm core IVRs was 10 ±
3, 7 ± 6 and 5 ± 5 respectively.
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3.2.2. ZA release
Similar to CG release, the ZA release is pooled from MZC and MZCL
for the same pore conﬁguration (Fig. 2a and b). Also, in agreement
with CG release, ZA release from500 μmpored core side IVRswas signif-
icantly lower than the release from 500 μm through pored IVRs
(p b 0.0001, adjusted p-value by Tukey–Kramer test method for multi-
ple comparisons b 0.0001) and 800 μm pored core side IVRs (p =
0.0015, adjusted p-value by Tukey–Kramer method for multiple
comparisons = 0.0042) while there was no signiﬁcant difference
between the release from 500 μm through and 800 μm core side IVRs
(p = 0.8393, adjusted p-value by Tukey–Kramer method for multiple
comparisons = 0.9775). Similar to the daily release proﬁle of CG, the
larger pored (800 μm) IVR approached target release rate at d50 and
the levels fell below the target value at d94. In contrast the 500 μm
pored core side IVRs showed a sustained release maintaining the levels
above or at the target values throughout the study. Also, release from
MZC and MZCL IVRs over time was not statistically signiﬁcant (p =
0.2126). The release of ZA scaled proportionally to CG loading (ZA: CG,
3:7). Through d31, the average CR (mg/d) was 11 ± 2 (35 ± 9% CR),
16 ± 2 (45 ± 7% CR) and 13 ± 3 (38 ± 7% CR) from 500 μm core
side, 500 μm through and 800 μm core side IVRs, respectively. Through
d31, the average daily release (mg/d) was 0.35 ± 0.1, 0.34 ± 0.1 and
0.23 ± 0.23 from 500 μm (core side), 500 μm (through) and 800 μm
core side pores, respectively. Post 94d release, the % ZA left in 500 μm
core, 500 μm through and 800 μm core IVRs was 8 ± 5, 4 ± 3 and
2 ± 2 respectively.
3.2.3. MIV-150 release
The releasemediumwasnon-sink, yielding a linear CR (and% CR) vs.
t plot, Fig. 2a. The daily release rate was constant (Fig. 2b). MIV-150
under the non-sink conditions crystallized on the surface of the IVRs
(conﬁrmed by HPLC analysis). Post 94d release, the % MIV-150 left in
500 μm core, 500 μm through, and 800 μm core IVRs was 35 ± 4,
31 ± 9 and 37 ± 2 respectively. A stability indicating HPLC method
indicated that MIV-150 was stable during the study period. Under sink
conditions in vitro MIV-150 demonstrates a ﬁrst order release as
expected from matrix systems (unpublished).
3.2.4. LNG release
The release medium was non-sink for LNG (Fig. 2a and b). Post 94d
release, the % LNG left in 500 μm core and 500 μm through IVRswas 9±
1% and 9 ± 2%, respectively. There was no LNG crystallization observed
during in vitro release studies as conﬁrmed by HPLC analysis, and LNG
was stable throughout the 94d release study.
3.3. Core–matrix IVRs released APIs in vivo for up to 28d
Although the IVRs released considerable levels of APIs in vitro, we
staged a 28d PK study (Fig. 3a) to test their performance in vivo in the
presence of cervical ﬂuid, blood, epithelial shedding, bacterial growth
(if any) in the core or pore, all of which could hinder the release of
core APIs. There was no change in vaginal pH over this period: baseline
pH was 7.0 ± 0.6 (n = 15) vs. 7.3 ± 0.9 (mean ± SD) during and post
study (n = 53, pooled time points for MZC/MZC IVRs). It should be
noted that the PK proﬁles generated in Fig. 3b resulted from analyzing
the concentrations of the swabs that were diluted in 1 mL of saline,
the net swab mass being unknown. This is a limitation of this study.
Therefore, the PK proﬁles are a conservative estimate of the VF concen-
tration and that the actual VF concentrations will be higher than repre-
sented in Fig. 3b.
3.3.1. CG release into vaginal ﬂuid (VF)
CG release from MZC/MZCL IVRs (Fig. 3b, top left) showed a lag of
about 24h, not observed in vitro. But once CG release began, the levels
increased steadily until d14 and thereafter persisted at ~50 μg/mL
(levels that protect mice from HSV-2 and HPV [43]) until the IVRs
were removed. There was a 2d lag in the 500 μm through MZC IVRs,
but thereafter the CG levels built up steadily until d19. For both MZC/
MZCL groups, the core side conﬁgurations (open symbols) showed a
steady release; the through IVRs (ﬁlled symbols) a more rapid decline.
The 800 μm core IVRs tended to release more CG relative to 500 μm
core IVRs, as observed in vitro and in vivo [52]. Although we were un-
able to achieve statistically signiﬁcant comparison due to high variabil-
ity seen in vivo and a limited number of animals tested per group,when
a larger sample size was tested this result was signiﬁcant [52]. As ex-
pected, there was no CG detected in macaques carrying placebo IVRs.
Taken together, the data strongly suggests that after the initial lag,
IVRs (irrespective of pore conﬁguration) continuously released CG
until IVR removal and without any indication of pore blockage. A repre-
sentativeMZCL IVR eluting ZC gel from the core is shown in Fig. 3c. Peak
CG release from 800 μm and 500 μm (core and through) IVRs was
27,000 and 7000 × IC50 of CG control (0.031 μg/mL) in the same assay.
3.3.2. VF MIV-150
MIV-150was detected (Fig. 3b, top right)within 1–4h PI (unlike CG)
and rapidly increased until 24h (burst) and declined gradually thereaf-
ter, which is characteristic of matrix based diffusion. The 800 μm pored
IVRs demonstrated a greater release at 24h and the levels (from all MZC
IVR conﬁgurations) decreased by 7d, but the MZCL IVRs showed
sustained levels for 14–19d. The variability observed within the groups
can be attributed to the same reasons as API variability in VF as
discussed earlier. But overall, all IVRs showed a ﬁrst order, matrix
based diffusion release. There was no MIV-150 detected in VF sampled
from macaques carrying placebo IVRs. From this data, for MZC IVRs at
24h, MIV-150 levels from 500 (core), 500 (through) and 800 (core)
IVRs, were 242–1448, 88–1075 and 907–2851 × IC50 of MIV-150
control (0.584 ng/mL) in the same assay. Similarly, in MZCL 500
(core) and 500 (through) IVRs at 24h, the levels were 181–455 and
414–987 × IC50 of MIV-150 control.
Fig. 1.Core–matrix IVR. (a) Photo of theMZCL IVR (20mm×4mm),macaque prototype, containingZA/CGcore (off-white ring) as seen through the translucent EVA-28matrix containing
MIV-150 and LNG and a pore to elute hydrated ZA/CG gel (scale: US dime=17.91mmdiameter). (b and c) Cross sections depicting core andmatrix compartments of the same IVRwith a
core side pore (b) and a drilled through pore (c) eluting ZA/CG gel.
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3.3.3. Blood MIV-150
MIV-150 was detected within 30 min PI (Fig. 3b, bottom left). The
levels attained in the blood were more consistent than in VF. There
were a few notable observations — the 500 through IVRs showed a
higher release at the onset in the MZC group (no corresponding data
available for that time point in the MZCL group). Signiﬁcantly greater
amounts of MIV-150 were released from MZCL IVRs on days 3 (p =
0.0087) and 7 (p = 0.0046), one-way ANOVA, relative to the MZC
IVRs but thereafter the kinetics for both groups overlapped. The release
was ﬁrst order (burst and decline), comparable to the kinetics of MIV-
150 in VF. Therewas noMIV-150 detected in plasma collected fromma-
caques carrying placebo IVRs. The crystallization of MIV-150 seen
in vitro was not observed post in vivo studies, which suggests that
MIV-150 released under sink conditions in vivo. Based on this PK proﬁle
we computed other PK parameters as follows: AUC48h–∞:
1.2 ng·d·mL−1 (MZC IVR) and 1.5 ng·d·mL−1 (MZCL IVR). For MZCL
IVR, Cmax (0–∞) was 0.36 ng/mL at 24h (Tmax). For MZCL IVR the ﬁrst
time point was measured at 48h so Cmax (48h–∞) was 0.4 ng/mL at 48h
(Tmax). Overall, only sub-nanogram levels of MIV-150 were detected
in blood during IVR use.
3.3.4. Blood LNG
LNG levels spiked rapidly in the ﬁrst 24h (similar to MIV-150) and
declined gradually, consistent with matrix based diffusion release.
Also like MIV-150, the 500 μm through IVRs tended to release more
LNG at the initial time points (4–24h) but not thereafter. No LNG was
detected in the MZC IVR group, as expected. The average LNG levels
from the MZCL IVRs on the last day (d23) of use were 355 ±
88 pg/mL, level associated with contraceptive activity [63,64]. Based
on the PK proﬁle, other PK parameters were computed as follows:
AUC48h–∞ was 8.07 ng·d·mL−1 (MZCL, 500 core) and 10.2 ng·d·mL−1
(MZCL, 500 through) at Cmax (0–∞) of 24h. Average LNG AUC0–∞for
MZCL IVRs was 9.14 ng·d·mL−1.
The residual APIs in the IVRs after the PK study is seen in Fig. 4. Over-
all, the % of APIs remaining in the different IVRs were not different
(Fig. 4a), (p = 0.55, one-way ANOVA). The residual ZA and CG levels
Fig. 3. PK proﬁles of APIs fromMZC andMZCL IVRs with varying pore conﬁgurations in non-DP treatedmacaques. (a) Schematic representation of PK study timeline for IVR insertion and
removal, pH measurement and sample collection at indicated timepoints (b) CG and MIV-150 levels (upper row) in VF from MZC IVRs of 500 μm pore (core side, n = 10), 500 μm pore
(through, n=11), 800 μmpore (core side, n=4) andMZCL IVRs of 500 μmpore (core side, n=3) and 500 μmpore (through, n=3). MIV-150 and LNG levels (bottom left) in blood from
the same rings. Data represents mean± SEM. **p b 0.01 (MZC vs. MZCL) (c) Image of anMZCL IVRwith 800 μmpore IVR removed post 21d in vivo insertion (as collected from the lumen
with no further post-treatment). The ZA/CG from the core released as a gel (arrow) demonstrating proof-of-concept. The IVR dimensions are same as that in Fig. 1A.
Fig. 2. In vitro release of APIs from novel core–matrix IVRs. (a) Cumulative release (mean± SD) as a function of time of hydrophilic (core) APIs— CG and ZA (upper row) under sink con-
ditions and hydrophobic (matrix) APIs — MIV-150 and LNG under non-sink conditions (bottom row) from the same rings. Release of APIs from — 500 μm core side pore, n = 5, (data
pooled for MZC and MZCL IVRs), 500 μm through pore, n = 5, (data pooled for MZC and MZCL IVRs) and 800 μm core side pore, n = 3, (MZC IVRs). (b) Daily release as a function of
time of the same rings as (a). Dotted lines represent target daily release. The data is pooled as the IVR type, MZC vs. MZCL, did not affect API release in vitro over time. (c) Unhydrated
IVR core (d0) and progressive hydration of the core during 10d in vitro release. ZA/CG gel eluted from the pore by d1. The IVR dimensions are same as that in Fig. 1.
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(Fig. 4b) correlated signiﬁcantly (Spearman analysis, p b 0.0001, two-
tailed), but the correlation was not signiﬁcant for residual MIV-150
and LNG probably because of the small number of IVRs available for
analysis (Fig. 4b).
3.3.5. Vaginal ﬂuid ZA release
Zinc levels in VFwere below the LLOQof our current assay (15 μg/mL
in VF). But the correlation between residual % CG and %ZA (Fig. 4b) was
signiﬁcant, implying that CG and ZA were released concomitantly.
3.4. MZC combination does not affect activity of LNG and vice versa
McPhail index scores (Table 3) and histological evaluations (data not
shown) conﬁrmed that the progestational activity observed in response
to LNG was not signiﬁcantly different when LNG was co-administered
withMIV-150 and ZA. Also, LNGdid not interferewith the potency of in-
dividual or combined APIs (Table 4). This LNG concentration represents
a much higher ratio ([LNG]/[antiviral APIs]) than the amounts released
from the IVRs, suggesting no interference with the activities of other
APIs. There was no toxicity at all concentrations tested in the antiviral
and cytotoxicity assays (data not shown).
3.5. In vitro and in vivo released APIs are active
After conﬁrming that LNG and MZC did not interfere with their re-
spective activities, we veriﬁed the activities of in vitro and in vivo re-
leased APIs using established in vitro cell-based assays. APIs released
in vitro and in vivo were active against HIV-1ADA-M, HSV-2 and HPV
16- PsV (Fig. 5, Table 5). The IC50 values of the test samples were com-
parable to the respective controls (within 95% CI), native API compo-
nents, which were tested concurrently in the same assay. No CC50
values are shown since cell viability was nearly 100% at all dilutions
tested, in all antiviral assays. In order to assess ZA contribution, the
assay requires a pre-incubation step of 6h, which skews the signal-to-
noise ratio. Hence only CG's efﬁcacy (but not zinc's) against HSV-2
could be tested, yielding higher IC50 (otherwise much lower as seen in
Table 4).
3.6. Stability of APIs in the MZCL IVRs
The percent recoveries of all four APIs in MZCL IVRs (n= 3, mean±
SD) at threemonths, 40 °C/75% RHwere 91± 11%MIV-150 (p= 0.19),
97 ± 5% LNG (p = 0.69), 106 ± 3.8% CG (p = 0.08) and 96 ± 6% ZA
(p= 0.33). The stability indicating HPLCmethod showed no additional
API peaks, thereby conﬁrming stability of MIV-150 and LNG in the IVR
matrix. ZA/CG are stable at pH 4.2 for 3 months at 40 °C/75% RH
(unpublished).
4. Discussion
Common viral STIs like HSV-2 and HPV increase susceptibility to
HIV-1 infection and cause other serious health conditions in women
[11–15]. An MPT-IVR that can simultaneously prevent these STIs and
unintended pregnancy for 90d could be an affordable and acceptable
[31] solution, particularly for women in resource-poor regions. Recog-
nizing the limitations of the conventional matrix type IVRs, several
groups have developed new IVR technologies for controlled and
sustained delivery of hydrophilic APIs for up to 30d. Release of biological
macromolecules from an insert IVR [65], and a ﬂux control pump tech-
nology [66] has been reported. Baum et al. [67] demonstrated release of
two hydrophilic small molecules from a pod-IVR (can accommodate up
to 10 pods). Essentially, the APIs were formulated in elastomeric or
highly compressible hydrophilic matrices which were inserted in the
main body of the IVR. The resulting reservoirs were discontinuous
along the IVR length whereas the IVR design proposed in this work
has a continuous core. TheMPT IVRwe developed contained a combina-
tion microbicide composed of three APIs (active against HIV-1, HSV-2
and HPV) and a contraceptive which we tested in vitro for 94d and in
macaques for up to 28d. A notable feature of the IVR is its ability to si-
multaneously deliver hydrophilic and hydrophobic APIs of different
MWs from a simple polymeric toroid.
The dose ranging studies of ZA in CG gels at a high HSV-2 challenge
in mice showed that ZA content had to be at least 1/10 of CG loading
[47] to show signiﬁcant protection. The IVR core loading of 3/7 (ZA/
CG) maintains this criterion and yields a compact core upon compres-
sion. We selected MIV-150 loading based on dose ranging studies
where 3 mg MIV-150/ IVR signiﬁcantly protected macaques from
SHIV-RT infection in a high dose viral challenge [51]. The LNG dose for
a human IVRwas scaled down for amacaque IVR [68]. The target release
values for the microbicides are at least 1000 times their reported EC50
values and for LNG, 10,000 times above its reported minimum effective
level, 200 pg/mL [64].
In vitro, ZA/CG release from MZCL IVRs was sustained for 94d; con-
trolled (zero order) for ﬁrst 18–31d, butﬁrst order thereafter (rate of re-
lease declined steadily). Upon contact with the (aqueous) release
Fig. 4. Residual APIs in the IVRs post-PK study. (a) IVRs used in the PK study were analyzed for residual API content. The plot shows % APIs (core and matrix APIs) remaining in the IVRs.
(b) Plot indicating correlation between residual core APIs, CG and ZA, using Spearman analysis. The correlation was signiﬁcant indicated by p b 0.0001. (c) The correlation was not signif-
icant for MIV-150 and LNG at the ‘n’s tested.
Table 3
MZC combination does not interfere with progestational activity of LNG.
Test gel McPhail indexa
(mean)b
Histology
CG/LNG (50 μg LNG/mL) 1.25 Low glandular transformation
CG/LNG (150 μg LNG/mL) 3.40 High glandular transformation
MZC (0 μg LNG/mL) 0 No glandular transformation
MZCL (50 μg LNG/mL) 1.13 Low glandular transformation
MZCL (150 μg LNG/mL) 3.25 High glandular transformation
a McPhail index scored byhistological evaluationof endometrial glandular development
and transformation.
b Average index from 4 female rabbits per group.
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medium, there was inﬂux of buffer into the ZA/CG reservoir through
the pore. Within the core, the compressed ZA/CG pellet started
transitioning into a supersaturated gelled mass. The solvent front was
seen progressing gradually in the dry core for the ﬁrst few days until
the core became fully hydrated. As the hydration continued, volume ex-
pansion led to the expulsion of the ZA/CG gel which subsequently dis-
solved in the release medium. ZA/CG gel eluted by d1. Initially, under
sink conditions, the concentration of the APIs in the core (C0) is much
greater than the concentration in the release medium (Cm); C0⋙ Cm.
The core APIs released at a steady state (SS) until (constant) concentra-
tion gradient was maintained between the core and the outside medi-
um. But as the core continued to deplete, the constant concentration
gradient between C0 and Cm that drives the zero order, or SS, release
was not maintained and the release rate declined steadily and
transitioned to a ﬁrst order release. Nevertheless, the levels of released
CGwere greater than 100 μg/mL throughout; CG at ~50 μg/mLprotected
mice fromHPV and HSV-2 infections [26]. ZA release kineticsmimicked
that of CG except that the release rate scaled proportionally to the ZA/
CG loading, indicating that CG acts as a carrier for ZA.
The pore conﬁguration inﬂuenced the API release rates. The smaller
pored IVRs (500 μm)with 1 pore (core side conﬁguration)maintained a
longer linear release proﬁle (up to 31d) whereas in the 500 μm pored
IVRs with 2 pores (through conﬁguration) or larger pored (800 μm)
IVRs, controlled release was observed for up to 18d. For both CG and
ZA, the overall release rate from the 500 μm pored core side IVRs was
signiﬁcantly lower than 500 μm pored through and 800 μm pored core
side IVRs. Gunawardana [69] also reported different release rates of
humanmonoclonal antibodies froman IVR as a function of pore size. To-
bias et al. [70] showed that SS steady can be extended by increasing the
payload in an osmotic device made from biodegradable elastomer,
keeping pore size constant. Thus, by scaling the currentmacaque proto-
type to a human IVRwhere the core capacity will increase by 2.5–3 fold,
we can expect that the SS can be extended. Release rate is an inverse
function of themembrane thickness and alongwith pore size can be op-
timized to yield the desired release rate. The membrane thickness in all
the IVRs we tested was 1 mm. The core API release was not affected by
the addition of LNG toMZC combination. In vivo, the LNG andMZC com-
bination was compatible; neither LNG nor MZC affected each other's
bioactivity. The release conditions were non-sink for matrix APIs, MIV-
150 and LNG, and the SS observed was a result of the saturation of the
media. The primary goal of the release studies was to characterize CG
and ZA elution from the IVRs via a pore continuously for 90d. Therefore,
we did not adjust the release conditions by incorporating solubilizers or
by increasing the volume (compromised detection of ZA) to provide
sink conditions for MIV-150 and LNG. The non-sink conditions used in
in vitro studies demonstrates that hydrophobic APIs were released
from the prototype IVRs but does not characterize actual device
Table 4
LNG does not impede antiviral activity of APIs included in MZC combination.
IC50 (95% conﬁdence interval)
Compounda Anti-HIV (nM for
MIV-150, μm for ZA)
Anti-HSV-2
(μg/mL)
Anti-HPV
(ng/mL)
MIV-150 1.03 (0.79–1.34) n/a n/a
MIV-150 + LNG 0.60 (0.32–1.13) n/a n/a
CG n/a 0.010
(0.007–0.014)b
22.8
(18.2–22.5)
CG + LNG n/a 0.008
(0.004–0.010)b
11.5
(10.3–12.8)
ZA 57.6 (29.9–110.8) 18.5 (14.3 to 23.9) n/a
ZA + LNG 71.9 (43.5–119) 13.6 (10.6–17.5) n/a
ZA + MIV-150 20.7 (10.9–39.5) n/a n/a
ZA + MIV-150 + LNG 30.1 (23.7–38.2) n/a n/a
CG + ZA n/d 0.006
(0.006–0.007)b
n/d
CG + ZA + LNG n/d 0.005
(0.005–0.006)b
n/d
n/a = not applicable; n/d = not determined.
a IC50 values are for the underlined compound.
b CGanti-HSV-2 IC50 values are different from those shown in Fig. 5 because in this table
virus and compounds were pre-incubated before adding to cells while in Fig. 5 they were
added at once to cells.
Fig. 5. APIs released fromMZC andMZCL IVRswere active in vitro and in vivo (a) Eluent from the in vitro release study (days 1, 25, 46 and 94, pooled). The ﬁgure representsmean± SD of
samples from 12 replicateMZCL IVRswith each dilution run in triplicate. (b) Activity in vaginal ﬂuid (swabs collected frommacaques that receivedMZC orMZCL IVRs (n=8) and placed
in 1 mL of saline). Data is for 48h for HIV-1, 7 days for HPV and day 17 HSV-2 (with exception of 1 sample which was 48h). The vertical lines are the IC50 values with 95% conﬁdence in-
tervals. All dilutions from each vaginal swab sample were run in triplicate, and the graph shows mean ± SD.
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behavior which is typically tested under sink conditions. Under sink
conditions, release of hydrophobic APIs from matrix EVA systems is
ﬁrst order release [36,71] and this was also supported by release of
MIV-150 and LNG in vivo in blood in the current study.
We staged in vivo studies to test the performance of the IVRs (partic-
ularly release of core APIs from a pore). The IVR formulations had not al-
tered the vaginal pH during the study period. The in vivo lag and
variability in CG release can be attributed to the physiological release
conditions (not encountered in vitro) and inter-macaque related differ-
ences — volume of ﬂuids (vaginal, cervical and blood) that vary during
cyclical phases and which are generally more viscous (contributing to
lag) than the in vitro release medium, varying distribution of CG as a
function of different vaginal vault sizes, and possibility of microbial
growth within the core or pore channel (no visual evidence of bacterial
growth). In addition, the amount of the VF diluted in 1 mL of saline was
not known, contributing to overall variability. But all the IVRs released
CG, following the lag, and the release persisted until the IVRs were re-
moved. Similar to in vitro release , the 800 μm pored IVR tended to
showgreater CG release than 500 μmpored IVRs and this result was sig-
niﬁcant [52]. These data demonstrate the feasibility of releasing a hy-
drophilic high MW API in a sustained manner from a non-water
swellable EVA matrix, otherwise suitable to elute hydrophobic small
molecules. The ZA and CG correlation upon use was signiﬁcant,
supporting the hypothesis that ZA released with CG. MIV-150 levels in
vaginal ﬂuid showed a ﬁrst order release. Macaques using MZCL IVRs
had signiﬁcantly higher levels of MIV-150 in blood at early time points
(d3 and d7) compared to macaques using MZC IVRs. This difference
was not signiﬁcant on d14 and at time points tested thereafter. A similar
trend was observed in a macaque efﬁcacy study [52]. At the levels of
LNG achieved in serum, contraceptive efﬁcacy has been reported [64]
in women. However it should be noted that Dusterberg et al. [72] re-
ported inter-species related variations in (%) bioavailabilities and plas-
ma half-lives of three different progestogens including LNG. As per
theirﬁndings, % bioavailability and plasmahalf-life of LNG in rhesusma-
caques was nearly 10 and 6 times (respectively) less than that reported
for women. Therefore, by accounting for the inter species related varia-
tion, the results presented here inform that the MZCL IVR is a suitable
system to deliver LNG at effective levels, however, serum LNG levels
as seen in macaques may in fact translate to much higher levels in
humans. Although the total loading of LNG per IVR was nearly 5 times
less than that of MIV-150, the levels of LNG detected in serum were
nearly 10 times greater than that of MIV-150 in plasma, suggesting a
more rapid systemic clearance of MIV-150. The effect of LNG in vivo is
being further investigated. In both, in vitro and in vivo studies, MIV-
150 and LNG being more hydrophobic will preferentially partition
from the surface of the IVR in to the surrounding (in vitro release medi-
um or tissues) by the Fick's law of diffusion. However, the inside of the
matrix is directly in contact with the hydrated core which has a volume
of ~100 μL. So, there will also likely be inward ﬂux of the hydrophobic
APIs in the core. ButMIV-150 and LNG, being hydrophobic, have limited
solubility in the aqueous phase and therefore the amount of hydropho-
bic APIs dissolved in the core will be considerably less than the amount
released in the external medium. The dissolved hydrophobic APIs in the
core will be transported (alongwith CG and ZA) to the outsidemedium
from the pore. Therefore, the levels detected in the surrounding medi-
um will be due to the diffusion of APIs from the IVR surface and a frac-
tion resulting from the core. The eluent from in vitro released studies
and VF containingMIV-150, CG and ZA (and LNG) retained their activity
against HIV-1, HSV-2 andHPV in cell-based assays. Also, in the presence
of semen, efﬁcacy of the APIs in VF was maintained [26,52].
After seeing promising PK and in vitro efﬁcacy results, we evaluated
MZCL IVRs for efﬁcacy in macaques under repeat SHIV-RT and HSV-2
co-challenge [52] ; the results indicated that there was signiﬁcant pro-
tection from SHIV-RT infection and reduced HSV-2 shedding frequency.
The results from the proof-of-concept PK studies presented here and
the efﬁcacy studies reported elsewhere [52] are encouraging. The next
steps for the human IVR development will involve evaluation of
EVA-28 and other suitable non-water swellable clinical grade polymers
(thermoplastic or silicone) that are approved for a long term use (90d).
Evaluation criteria include release characteristics of the APIs, ease of
scale-up, mechanical properties, stability and cost. Semi-solid core for-
mulations will also be explored to help overcome the lag in vivo. The
wall thickness, pore size, number of pores, core composition, loading
and mechanical strength will be optimized. Based on the IVR dimen-
sions, we expect to see a 3–4 fold increase in the core API payload in
the human IVR (relative to macaque IVR), which will likely yield an ex-
tended SS for up to 90d.
4.1. Clinical signiﬁcance of this IVR
Millions of women worldwide can beneﬁt from an MPT like the
MZCL IVR as it simultaneously protects against HIV-1, HSV-2, HPV and
unintended pregnancy. Its extended duration of action (one IVR per
90d) will also help reduce the cost, making the MPT MZCL IVR an
affordable option for low income populations. As the IVR delivers APIs
of diverse physicochemical properties, it can also be used to prevent
and/or treat other STIs like bacterial vaginosis, gonorrhea, and syphilis.
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